Capricor Therapeutics (NASDAQ:CAPR) Upgraded by B. Riley to “Strong-Buy” Rating

Capricor Therapeutics (NASDAQ:CAPR) was upgraded by analysts at B. Riley to a “strong-buy” rating in a report issued on Wednesday,Zacks.com reports.

Other research analysts also recently issued reports about the company. HC Wainwright restated a “buy” rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research note on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $30.00 target price on shares of Capricor Therapeutics in a research note on Wednesday, May 14th. Wall Street Zen downgraded shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Roth Capital reissued a “buy” rating and set a $31.00 price objective on shares of Capricor Therapeutics in a report on Tuesday, June 17th. Finally, Oppenheimer reduced their target price on Capricor Therapeutics from $43.00 to $22.00 and set an “outperform” rating on the stock in a report on Monday. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Capricor Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $33.75.

Capricor Therapeutics Stock Performance

Shares of CAPR stock opened at $10.18 on Wednesday. The stock has a fifty day simple moving average of $10.89 and a two-hundred day simple moving average of $12.38. The firm has a market capitalization of $465.02 million, a PE ratio of -7.17 and a beta of 0.84. Capricor Therapeutics has a 52-week low of $3.52 and a 52-week high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.20). The business had revenue of $2.73 million during the quarter, compared to the consensus estimate of $3.16 million. Capricor Therapeutics had a negative return on equity of 62.42% and a negative net margin of 181.71%. During the same period last year, the company earned ($0.31) EPS. On average, sell-side analysts forecast that Capricor Therapeutics will post -1.21 EPS for the current fiscal year.

Institutional Investors Weigh In On Capricor Therapeutics

Hedge funds have recently bought and sold shares of the business. Summit Investment Advisors Inc. grew its stake in shares of Capricor Therapeutics by 54.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock worth $53,000 after buying an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Capricor Therapeutics by 172.8% in the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock valued at $64,000 after acquiring an additional 2,947 shares during the last quarter. Virtus ETF Advisers LLC purchased a new position in Capricor Therapeutics in the fourth quarter worth about $68,000. AlphaQuest LLC bought a new stake in Capricor Therapeutics during the fourth quarter worth approximately $78,000. Finally, New York State Common Retirement Fund raised its position in Capricor Therapeutics by 625.0% during the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 5,000 shares during the period. Hedge funds and other institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.